Stay Informed with Real-Time Updates on the Current Stock Market
Eli Lilly surpasses expectations but lowers profit outlook Eli Lilly reported better-than-expected financial results for the third quarter, driven by strong demand for its diabetes drug Mounjaro. The pharmaceutical company reported earnings of $0.10 per share, surpassing estimates of a loss of $0.13 per share. Revenue also exceeded expectations, coming in at $9.50 billion compared …